美迪西已与多个公司在肿瘤免疫药物，如ADC，PD-1，双抗药物等的研发过程中合作共赢，帮助他们在研发申报过程中更顺利的拿到临床批件，推动研发进程。

2015年，FDA陆续批准PD-1抑制剂用于黑色素癌、肺癌和肾癌的治疗；此外还有更多癌症类型正在积极审批中，审批范围几乎囊括了所有实体瘤的范围；

Immune checkpoint blockade therapies have changed the paradigm of cancer therapies. Reseachers performed in vivo screening for anti-PD-1 therapy across 23 syngeneic tumor models and found that CT-26 and Colon 26, which are murine colorectal carcinoma derived from BALB/c mice, showed different sensitivity to anti-PD-1. In vivo studies for anti-PD-1 antibody across 23 syngeneic tumor models were performed by Medicilon.